Discover how NEO-201, an investigational monoclonal antibody, targets tumor-associated neoepitopes and abnormal O-glycans to enhance antibody-dependent cellular cytotoxicity (ADCC), reshape the tumor microenvironment, and potentially synergize with checkpoint inhibitors in solid tumor treatment.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs